# Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

> **NCT00985673** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 611 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK2340274A
- **BIOLOGICAL:** GSK2340273A
- **BIOLOGICAL:** Seasonal trivalent influenza vaccine (TIV)
- **BIOLOGICAL:** Saline placebo

## Key facts

- **NCT ID:** NCT00985673
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-01
- **Primary completion:** 2009-12-28
- **Final completion:** 2010-12-29
- **Target enrollment:** 611 (ACTUAL)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985673, "Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00985673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*